SEAGULL HEALTH
Your health,We care!
Its a targeted drug with precise efficacy, convenient administration, controllable safety profile, and prominent advantages in addressing specific disease indications.
AuthenticGuaranteeFast DeliveryPrivacy On January 16, 2025, Lietinib Tablets were approved for marketing by the National Medical Products Administration (NMPA). The drug is indicated for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after prior treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
On April 25, 2025, Lietinib Tablets obtained an additional approval as a first-line therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 substitution mutation (L858R).
On January 16, 2025, Aoyixin® (Liertinib Tablets, Investigational Code: ASK120067), a Class 1 chemical new drug and third-generation EGFR inhibitor, w···【Read More】
Update: 21 Jan,2026Source: Haiou HealthViews: 98
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
